Once-daily TRYVIO, now available to prescribe in the U.S., is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other medications. TRYVIO is the first-and-only dual endothelin receptor antagonist (ERA) for... read full story
Ask about this article
Related News
Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
PR Newswire 2024-11-13, 22:25Related News
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
PR Newswire2024-11-15, 22:36
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) (Decibel Therapeutics Inc)
Public Technologies2024-11-15, 07:02
LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Form 8 K (Lexicon Pharmaceuticals Inc)
Public Technologies2024-11-12, 21:54
Benuvia Operations, LLC and Department of Veterans Affairs Sign CRADA Agreement
PR Newswire2024-11-13, 14:21
Infusion Pump Market to Grow by USD 4.99 Billion (2024-2028), Driven by Rising Chronic Disease Cases, AI-Powered Report Explores Market Evolution - Technavio
PR Newswire2024-11-12, 22:58
